~~<i id='551DC2FABF'><strike id='551DC2FABF'><tt id='551DC2FABF'><pre id='551DC2FABF'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：leisure time 2025-09-29 02:04:30 Page View：713

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why hospitals are withdrawing from US News rankings
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Medicare has a new plan to address drug shortages

Medicarehasanewproposaltopayhospitalsmoretostockpileessentialdrugs,anefforttoavoidshortagesofchemoth

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

DarronCummings/APThebenefitsandrisksofEliLilly’streatmentforAlzheimer’sdiseasewereconfirmedindetaile